|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among these 6 genes, 3 transcription factors as well as the topoisomerase II alpha and the mitosis inhibitor WEE1Hu gene were significantly suppressed in the tumour cell lines.
|
10446455 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we analyze the kinase gene expression profiles of various tumor types and reveal the wee1 kinase to be overexpressed in glioblastomas.
|
20832752 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
|
21389100 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transfections using siWee1 in metastatic melanoma cell lines; WM239(WTp53), WM45.1(MUTp53) and LOX(WTp53), further support our hypothesis of a tumor promoting role of Wee1 in melanomas.
|
22719872 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo treatment of mice bearing OVCAR-5 xenografts with the combination of Chk1 and Wee1 inhibitors led to greater tumor growth inhibition than with the inhibitors used as single agents with no toxicity.
|
22713237 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that MK-1775, a potent and selective ATP-competitive inhibitor of WEE1, is cytotoxic across a broad panel of tumor cell lines and induces DNA double-strand breaks.
|
23699655 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Involvement of aurora kinase B (AURKB) and Wee1-like protein kinase (WEE1) as downstream proteins in the (V600E)B-RAF pathway was validated in xenografted tumors, and mechanisms of action were characterized in size- and time-matched tumors.
|
23416158 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, Wee1 siRNA treatment in tumor cells with an inherent loss of p53 activity results in a deregulated cell cycle that causes simultaneous DNA synthesis and premature mitosis and that these effects are kinase dependent.
|
24927813 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The main aim of this study was to asssess the tumor suppressive potential of WEE1 silencing in two different breast cancer cell lines, MCF7 which carries the wild-type p53 and MDA-MB468 which contains a mutant type.
|
24377575 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that sensitization to chemoradiation by WEE1 inhibition results from inhibition of HR repair and suggest that patient tumors without underlying HR defects would benefit most from this therapy.
|
26585231 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Taken together, our data suggest that CHEK1 or WEE1 inhibitors are likely to have greater clinical efficacy in tumors with RAD17 loss-of-function.
|
26437225 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclinical models.
|
27998224 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together with other recently published reports, our results add another level of evidence that the efficacy of WEE1 inhibition is influenced by the DNA repair status of a cell and may also be dependent on the tumor type and model evaluated.
|
27616351 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor suppressive effects of WEE1 gene silencing could not enhance immunopotentiation effects of CD80 and 4-1BBL co-stimulation in human T cells.
|
26881506 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors.
|
27077811 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have shown that genetic targeting AKT3 or WEE1 can be effective for inhibiting tumor growth in preclinical animal models.
|
28705772 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified several drug vulnerabilities and showed that the combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts tumours in vivo.
|
28854174 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results demonstrated that WEE1 mRNA expression was significantly increased in CRC tissues and that this upregulation correlated significantly with hepatic metastasis, distant metastasis and high tumor node metastasis (TNM) stage of CRC.
|
28599436 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Murine autochthonous and human transplant models were used to test the therapeutic efficacy and pharmacodynamic effects of dual treatment.<b>Results:</b> We demonstrate that combined inhibition of mTOR and WEE1 induced potent synergistic cytotoxic effects selectively in <i>KRAS</i>-mutant NSCLC cell lines, delayed human tumor xenograft growth and caused tumor regression in a murine lung adenocarcinoma model.
|
28821559 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AZD1775, an inhibitor against the critical G<sub>2</sub>-M checkpoint protein WEE1, is currently in clinical trials across a number of tumor types.
|
28652249 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Significantly, the WEE1 inhibitor AZD1775 not only abrogated the suppressive H2B Y37-phosphorylation and upregulated <i>IDH2</i> mRNA levels but also effectively reversed the 'loss of 5-hmC' phenotype in melanomas, GBMs and prostate cancer cells, as well as melanoma xenograft tumors.
|
29290954 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of vorinostat and AZD1775 inhibits tumor growth and angiogenesis <i>in vivo</i> in an orthotopic mouse model of oral cancer and prolongs animal survival.<b>Conclusions:</b> Vorinostat synergizes with AZD1775 in HNSCC cells with mutant p53 <i>in vitro</i> and <i>in vivo</i> A strategy combining HDAC and WEE1 inhibition deserves further clinical investigation in patients with advanced HNSCC.<i></i>.
|
28790110 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma.
|
30323762 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, the Wee1 inhibitor together with cytarabine or doxorubicin inhibited tumor growth <i>in vitro</i> and <i>in vivo</i> more effectively, providing a potential new therapy for treating B-cell lymphomas.
|
29217775 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry were performed on these tumor samples to analyze IDH1 mutation status and protein expression of WEE1. qRT-PCR, western blotting, transwell assays, and scratch wound healing assays were performed to evaluate the effect of WEE1 knockdown or overexpression in HGG cells.
|
29502292 |
2018 |